Pirh2 Antibody (YA5020)

Cat. No.: HY-P85328: Data Sheet User Guide for Antibodies
FAQs
Technical Support

Pirh2 Antibody (YA5020) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Pirh2.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

Pirh2 Antibody (YA5020) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Pirh2.

Host

Rabbit

Clonality

Monoclonal, Recombinant

Molecular Weight

Predicted band size: 30 kDa;

Observed band size: 30 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse

SwissProt ID

Q96PM5

Gene ID

25898 [NCBI]

Immunogen

A synthesized peptide derived from human RCHY1. The exact sequence is proprietary to MCE.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-2000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:50-200
IP IP: Immunoprecipitation	1:20-50

Sensitivity	Endogenous	Purity	affinity purified by Protein A
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG

Appearance

Liquid

Formulation

Supplied in 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：E3 ubiquitin-protein ligase that mediates ubiquitination of target proteins, including p53/TP53, TP73, HDAC1 and CDKN1B (PubMed:16914734, PubMed:17721809, PubMed:18006823, PubMed:19043414, PubMed:19483087, PubMed:21994467). Mediates ubiquitination and degradation of p53/TP53; preferentially acts on tetrameric p53/TP53 (PubMed:19043414, PubMed:19483087). Catalyzes monoubiquitinates the translesion DNA polymerase POLH (PubMed:21791603). Involved in the ribosome-associated quality control (RQC) pathway, which mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes: RCHY1 acts downstream of NEMF and recognizes CAT tails associated with stalled nascent chains, leading to their ubiquitination and degradation (PubMed:33909987); Has no E3 ubiquitin-protein ligase activity

Subcellular Localization：Nucleus; Nucleus speckle; Cytoplasm

Expression：
Induction:Up-regulated during the S phase of the cell cycle (PubMed:18006823) . Expressed at low levels during G phase (PubMed:18006823) ; Down-regulated in hepatocellular carcinoma

Isoforms & Post-Translational Modification：Q96PM5 has 8 isomers: Q96PM5-1: 30110 Da (predicted); Q96PM5-2: 28983 Da (predicted); Q96PM5-3: 20720 Da (predicted); Q96PM5-4: 21697 Da (predicted); Q96PM5-5: 8494 Da (predicted); Q96PM5-6: 27676 Da (predicted); Q96PM5-7: 25337 Da (predicted); Q96PM5-8: 24210 Da (predicted).
Subject to ubiquitination and proteasomal degradation. Interaction with PLAGL2 or KAT5 enhances protein stability

Subunit：Monomer and homodimer. Interacts with AR, MDM2, KAT5, PLAG1, PLAGL2, COPE, UBE2D2 and GORAB/NTKLBP1

Synonyms

RCHY1; ARNIP; CHIMP; PIRH2; RNF199; ZNF363; RING finger and CHY zinc finger domain-containing protein 1; Androgen receptor N-terminal-interacting protein; CH-rich-interacting match with PLAG1; E3 ubiquitin-protein ligase Pirh2; RING finger

Documentation

User Guide for Antibodies (1077 KB)